In colorectal and non-small-cell lung cancers, resistance to EGFR inhibitors develops due to secondary mutations in EGFR (38, 39) or mutations in downstream effectors such as KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) or BRAF (40, 41). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.